Coronavirus – New study: Sotrovimab neutralizing antibody protects against serious disease

Get real time updates directly on you device, subscribe now.

His pandemic coronavirus is in progress around the world and the increase in cases is expected to strengthen the pressure on health systems as the number of patients treated with Covid-19 will increase. Good news brings a new one study recently published for sotrovimab, one monoclonal antibody that neutralizes SARS-CoV-2 as well as many other sorbekoviruses.

The doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Giannis Danasis, Panos Malandrakis and Thanos Dimopoulos (Rector of EKPA) summarize the results of study by Anil Gupta et al. recently published (27/10) in the prestigious scientific journal “The New England Journal of Medicine”, entitled “Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab”.

According to the Athenian-Macedonian News Agency, this is a multicenter, double-blind phase 3 study in whichincluded patients with symptomatic Covid-19 disease who did not require hospitalization but with risk factors for severe disease and had symptoms for less than 5 days. Patients were randomized to a 1: 1 ratio to receive a 500 mg sotrovimab infusion or placebo. Participants were monitored for 29 days from inclusion in the study and hospitalizations and deaths for any cause were evaluated.

What the studies showed

The researchers analyzed data from 583 patients, of whom 291 received sotrovimab and 292 received placebo. Three patients with Covid-19 (1%) from the receiving group sotrovimab in contrast, 21 patients with Covid-19 (7%) from the placebo group had to be hospitalized or died (relative risk reduction of 85% with sotrovimab). Among the placebo-treated patients, 5 patients were admitted to the intensive care unit and 1 was completed by the 29th day of study enrollment. Regarding the security of drug, the data concern 868 patients in the study (430 in the sotrovimab group and 438 in the placebo group). Adverse reactions were reported in 17% of patients receiving sotrovimab and 19% of placebo.

In conclusion, high-risk patients with mild to moderate Covid-19 disease receiving Sotrovimab out of hospital reduced the likelihood of disease exacerbation, while no drug safety issues were identified.

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.